TAVI may support use in intermediate-risk severe AS; leaves open long-term durability versus SAVR.
Transcatheter aortic valve implantation (TAVI) has become a therapeutic alternative for patients presenting with severe symptomatic aortic stenosis and considered either at high (1,2) or intermediate preoperative risk (3,4) for surgical aortic valve replacement (SAVR).
No takes yet. Share an insight, caveat, or question.
Bagur et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: